Receptor News and Research

RSS

Increased replicative fitness of SARS-CoV-2 UK strain in human bronchial cells

A recent study from France showed that the UK variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – also known as B.1.1.7 variant – can replicate much more efficiently in a reconstituted human bronchial epithelium, which may explain why it spreads so rapidly in the human population. The study is currently freely available on the bioRxiv preprint server.

24 Mar 2021

Deep learning tool predicts hosts based on early SARS-CoV-2 samples

The study, which appeared on the pre-print server bioRxiv*, revealed how DeepHoF could help prevent future outbreaks that may become as large as the current pandemic.

24 Mar 2021

Repurposed heart and flu drugs that protect platelets improve survival of septic mice

Despite continued improvements in antibiotics and hospital intensive care, staph sepsis - a bloodstream infection caused by Staphylococcus aureus bacteria - still causes severe illness or death in 20 to 30 percent of patients who contract it.

24 Mar 2021

New compound may provide a basis for drug development against COVID-19

SARS-CoV-2, the virus responsible for the COVID-19 pandemic, arrived one year ago and turned our lives upside-down.

24 Mar 2021

Three commonly used antiviral drugs potentially effective at preventing replication of SARS-CoV-2

An international team of researchers has found that three commonly used antiviral and antimalarial drugs are effective in vitro at preventing replication of SARS-CoV-2, the virus that causes COVID-19.

24 Mar 2021

Researchers examine acriflavine's antiviral potential against SARS-CoV-2

Acriflavine is traditionally employed as a topical antiseptic, though has more recently been implicated as an antiviral agent at low doses, potentially by stimulating the production of interferon. In a new study recently uploaded to the bioRxiv* preprint server, the application of the drug to SARS-CoV-2 infection is investigated, demonstrating a broad activity towards a range of other betacoronaviruses.

24 Mar 2021

Reduced mRNA COVID-19 vaccine response in nursing home residents

A recent study has examined the response of nursing home residents who were naïve to SARS-CoV-2 infection following vaccination by the mRNA BNT162b2 model from Pfizer-BioNTech.

24 Mar 2021

Pangolin coronavirus sheds light on UK SARS-CoV-2 variant's evolutionary trajectory

Researchers at the Division of Infection and Immunity, University College London, UK, have provided key insights into the characteristics of the B.1.1.7 (or UK) variant of SARS-CoV-2.

24 Mar 2021

Modeling study predicts SARS-CoV-2 variants with high receptor binding affinity

A new study adds to the sum of knowledge about SARS-CoV-2, with respect to its natural and biologically significant mutations, using computational modeling of the virus-receptor interactions. Understanding how viral mutations affect the virus-host interactions is crucial for shaping proper strategies to control the virus.

24 Mar 2021

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

A new study reports the essential nature of Fc-mediated functionalities in determining the efficacy of such antibodies.

24 Mar 2021

New covalent and non-covalent SARS-CoV-2 inhibitors discovered in silico

A new study describes the use of a combination of virtual and experimental screening protocols to identify potential inhibitors of the virus, which could lead to rapid drug development.

24 Mar 2021

Research suggests toothpaste and mouthwash ingredients could help prevent SARS-CoV-2 infection

Now, new research published on the bioRxiv preprint server focuses on the effect of some typical ingredients present in commercially available mouthwashes and toothpaste on the mechanisms of SARS-CoV-2 entry into host cells.

24 Mar 2021

Checkpoint inhibition could offer an effective treatment option for patients with rare cancer

Peritoneal mesothelioma is cancer that develops in the lining of the abdomen, which is known as the peritoneum.

24 Mar 2021

Glycans play a key role in COVID-19 infection, shows study

A research group at the RIKEN Center for Computational Science (R-CCS) has found that glycans—sugar molecules—play an important role in the structural changes that take place when the virus which causes COVID-19 invades human cells.

24 Mar 2021

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

In a new study, published recently on the bioRxiv preprint server, researchers isolated a nanobody that potently neutralizes SARS-CoV-2, including the B.1.351 variant, and cross-neutralizes SARS-CoV. They demonstrated the therapeutic potential of the nanobody in a human ACE2 (angiotensin-converting enzyme) transgenic mouse model.

24 Mar 2021

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

The CVnCoV mRNA vaccine showed neutralizing antibody levels and completely protected mice infected with the B.1.351 variant. No viral genomes were seen in oral swabs, lungs, or brain.

23 Mar 2021

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

A recent study by researchers from Philadelphia, currently available on the medRxiv preprint server, shows that individuals with prior infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit substantial immune memory and develop a robust response to the first dose of an mRNA vaccine.

23 Mar 2021

Computational analysis reveals why new SARS-CoV-2 variants bind better to human cells

All viruses mutate as they make copies of themselves to spread and thrive. SARS-CoV-2, the virus the causes COVID-19, is proving to be no different. There are currently more than 4,000 variants of COVID-19, which has already killed more than 2.7 million people worldwide during the pandemic.

23 Mar 2021

Is T-cell receptor sequencing a reliable alternative to SARS-CoV-2 antibody testing?

Researchers in the United States have now demonstrated that T-cell receptor (TCR) sequencing might provide a reliable alternative to assessing infection in convalescent blood plasma, and may be applicable in the future for applying protective immunity to individuals.

23 Mar 2021

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

A Korea-based company EyeGene Inc. has recently developed a liposome-based mRNA candidate vaccine against COVID-19, which contains full-length spike protein of the European variant (D614G) of SARS-CoV-2 as a vaccine antigen.

23 Mar 2021

Receptor News and Research

Increased replicative fitness of SARS-CoV-2 UK strain in human bronchial cells

Deep learning tool predicts hosts based on early SARS-CoV-2 samples

Repurposed heart and flu drugs that protect platelets improve survival of septic mice

New compound may provide a basis for drug development against COVID-19

Three commonly used antiviral drugs potentially effective at preventing replication of SARS-CoV-2

Researchers examine acriflavine's antiviral potential against SARS-CoV-2

Reduced mRNA COVID-19 vaccine response in nursing home residents

Pangolin coronavirus sheds light on UK SARS-CoV-2 variant's evolutionary trajectory

Modeling study predicts SARS-CoV-2 variants with high receptor binding affinity

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

New covalent and non-covalent SARS-CoV-2 inhibitors discovered in silico

Research suggests toothpaste and mouthwash ingredients could help prevent SARS-CoV-2 infection

Checkpoint inhibition could offer an effective treatment option for patients with rare cancer

Glycans play a key role in COVID-19 infection, shows study

Potent nanobody binds SARS-CoV-2 spike in an extraordinary manner

CureVac's COVID-19 vaccine protects mice against emerging SARS-CoV-2 variants

Study shows single dose of mRNA vaccine may suffice for those with prior SARS-CoV-2 infection

Computational analysis reveals why new SARS-CoV-2 variants bind better to human cells

Is T-cell receptor sequencing a reliable alternative to SARS-CoV-2 antibody testing?

A new COVID-19 candidate vaccine induces robust humoral and cellular immune responses in mice

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News